<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="829">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332720</url>
  </required_header>
  <id_info>
    <org_study_id>3682-012</org_study_id>
    <secondary_id>2014-003347-35</secondary_id>
    <nct_id>NCT02332720</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3 Infection (MK-3682-012)</brief_title>
  <official_title>A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT3 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, three-part, parallel-group, open-label trial of grazoprevir (MK-5172)
      (100 mg) and MK-3682 (300 mg or 450 mg) with either elbasvir (MK-8742) (50 mg) or MK-8408
      (60 mg), and with and without ribavirin (RBV), in treatment-naive (TN) or
      treatment-experienced (TE) cirrhotic (C) or non-cirrhotic (NC) participants infected with
      hepatitis C virus (HCV) genotype (GT) 3. Part A will consist of 4 arms to evaluate the
      safety of dose combinations. In Part B, participants will take 2 MK-3682B fixed dose
      combination (FDC) tablets once daily (q.d.) by mouth, with or without twice-daily (b.i.d.)
      RBV (200 mg capsules; weight-based dosing). Participants who relapse following completion of
      therapy in Part A will be offered the option of retreatment with 16 weeks of MK-3682B with
      RBV in Part C (data obtained from Part C will not be used in the analysis of outcome
      measures).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A, study therapy will be administered as separate products, each taken q.d. by
      mouth. In Part B and Part C, participants will take 2 MK-3682B FDC tablets q.d. by mouth;
      each MK-3682B FDC tablet contains grazoprevir 50 mg + MK-3682 225 mg + MK-8408 30 mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants achieving SVR12</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who had study drug discontinued due to an AE</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving SVR24</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>19</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1 Part A: GT3 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC participants will take grazoprevir (100 mg) + MK-3682 (300 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Part A: GT3 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC participants will take grazoprevir (100 mg) + MK-3682 (300 mg) + MK-8408 (60 mg) q.d. by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Part A: GT3 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC participants will take grazoprevir (100 mg) + MK-3682 (450 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Part A/B: GT3 NC TN Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + MK--3682 (450 mg) + MK-8408 (60 mg) q.d. by mouth for 8 weeks. In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B tablets q.d. by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Part B: GT3 NC TN MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC TN participants will take 2 MK-3682B tablets q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 Part B: GT3 NC TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC TN participants will take 2 MK-3682B tablets q.d. by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 Part B: GT3 NC TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected C participants will take 2 MK-3682B tablets q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 Part B: GT3 NC TE MK-3682B (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC TE participants will take 2 MK-3682B tablets q.d. by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 Part B: GT3 NC TE MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC TE participants will take 2 MK-3682B tablets q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 Part B: GT3 NC TE MK-3682B (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC TE participants will take 2 MK-3682B tablets q.d. by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11 Part B: GT3 NC TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC TE participants will take 2 MK-3682 tablets q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 Part B: GT3 NC TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected NC TE participants will take 2 MK-3682B tablets q.d. by mouth for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13 Part B: HCV GT3 C TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected C TN participants will take 2 MK-3682B tablets q.d. by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14 Part B: HCV GT3 C TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT-infected C TN participants will take 2 MK-3682B tablets q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 Part B: HCV GT3 C TN MK-3682B (16 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected C TN participants will take 2 MK-3682B tablets q.d. by mouth for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 Part B: HCV GT3 C TE MK-3682 B (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected C TE participants will take 2 MK-3682B tablets q.d. by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>17 Part B: GT3 C TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected C TE participants will take 2 MK-3682B tablets q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18 Part B: GT3 C TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected C TE participants will take 2 MK-3682B tablets q.d. by mouth for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>19 Part B: GT3 C TE MK-3682B + RBV (16 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT3-infected C TE participants will take 2 MK-3682B tablets q.d., and RBV (weight-based dosing) b.i.d., by mouth for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir</intervention_name>
    <description>One grazoprevir 100 mg tablet (Part A), or two MK-3682B tablets each containing grazoprevir 50 mg (Part B), taken q.d. by mouth.</description>
    <arm_group_label>1 Part A: GT3 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>2 Part A: GT3 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>3 Part A: GT3 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>4 Part A/B: GT3 NC TN Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>5 Part B: GT3 NC TN MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>6 Part B: GT3 NC TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>7 Part B: GT3 NC TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>8 Part B: GT3 NC TE MK-3682B (8 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT3 NC TE MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>10 Part B: GT3 NC TE MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>11 Part B: GT3 NC TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>12 Part B: GT3 NC TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>13 Part B: HCV GT3 C TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: HCV GT3 C TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>15 Part B: HCV GT3 C TN MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>16 Part B: HCV GT3 C TE MK-3682 B (12 weeks)</arm_group_label>
    <arm_group_label>17 Part B: GT3 C TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>18 Part B: GT3 C TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>19 Part B: GT3 C TE MK-3682B + RBV (16 weeks)</arm_group_label>
    <other_name>MK-5172</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3682</intervention_name>
    <description>Two or three MK-3682 150 mg (300 or 450 mg total daily dose) tablets (Part A), or two MK-3682B tablets each containing MK-3682 225 mg (Part B), taken q.d. by mouth.</description>
    <arm_group_label>1 Part A: GT3 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>2 Part A: GT3 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>3 Part A: GT3 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>4 Part A/B: GT3 NC TN Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>5 Part B: GT3 NC TN MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>6 Part B: GT3 NC TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>7 Part B: GT3 NC TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>8 Part B: GT3 NC TE MK-3682B (8 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT3 NC TE MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>10 Part B: GT3 NC TE MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>11 Part B: GT3 NC TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>12 Part B: GT3 NC TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>13 Part B: HCV GT3 C TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: HCV GT3 C TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>15 Part B: HCV GT3 C TN MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>16 Part B: HCV GT3 C TE MK-3682 B (12 weeks)</arm_group_label>
    <arm_group_label>17 Part B: GT3 C TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>18 Part B: GT3 C TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>19 Part B: GT3 C TE MK-3682B + RBV (16 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir</intervention_name>
    <description>One elbasvir 50 mg tablet (Part A), taken q.d. by mouth.</description>
    <arm_group_label>1 Part A: GT3 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>3 Part A: GT3 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <other_name>MK-8742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8408</intervention_name>
    <description>Six MK-8408 10 mg (60 mg total daily dose) capsules (Part A), or two MK-3682B tablets each containing MK-8408 30 mg (Part B), taken q.d. by mouth.</description>
    <arm_group_label>2 Part A: GT3 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>4 Part A/B: GT3 NC TN Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>5 Part B: GT3 NC TN MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>6 Part B: GT3 NC TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>7 Part B: GT3 NC TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>8 Part B: GT3 NC TE MK-3682B (8 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT3 NC TE MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>10 Part B: GT3 NC TE MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>11 Part B: GT3 NC TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>12 Part B: GT3 NC TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>13 Part B: HCV GT3 C TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: HCV GT3 C TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>15 Part B: HCV GT3 C TN MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>16 Part B: HCV GT3 C TE MK-3682 B (12 weeks)</arm_group_label>
    <arm_group_label>17 Part B: GT3 C TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>18 Part B: GT3 C TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>19 Part B: GT3 C TE MK-3682B + RBV (16 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3682B</intervention_name>
    <description>Two FDC tablets, each containing grazoprevir 50 mg + MK-3682 225 mg + MK--8408 30 mg (Part B), taken q.d. by mouth.</description>
    <arm_group_label>4 Part A/B: GT3 NC TN Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>5 Part B: GT3 NC TN MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>6 Part B: GT3 NC TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>7 Part B: GT3 NC TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>8 Part B: GT3 NC TE MK-3682B (8 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT3 NC TE MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>10 Part B: GT3 NC TE MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>11 Part B: GT3 NC TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>12 Part B: GT3 NC TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>13 Part B: HCV GT3 C TN MK-3682B (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: HCV GT3 C TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>15 Part B: HCV GT3 C TN MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>16 Part B: HCV GT3 C TE MK-3682 B (12 weeks)</arm_group_label>
    <arm_group_label>17 Part B: GT3 C TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>18 Part B: GT3 C TE MK-3682B (16 weeks)</arm_group_label>
    <arm_group_label>19 Part B: GT3 C TE MK-3682B + RBV (16 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.</description>
    <arm_group_label>5 Part B: GT3 NC TN MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>7 Part B: GT3 NC TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT3 NC TE MK-3682B + RBV (8 weeks)</arm_group_label>
    <arm_group_label>11 Part B: GT3 NC TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: HCV GT3 C TN MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>17 Part B: GT3 C TE MK-3682B + RBV (12 weeks)</arm_group_label>
    <arm_group_label>19 Part B: GT3 C TE MK-3682B + RBV (16 weeks)</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has documented chronic HCV GT3 with no evidence of non-typeable or mixed GT infection

          -  Is otherwise healthy as determined by the medical history, physical examination,
             electrocardiogram (ECG), and clinical laboratory measurements performed at the time
             of screening

          -  Has cirrhosis of the liver (Part B only) or is non-cirrhotic (Part A and B)

          -  Is HCV treatment-naïve or has experienced virologic failure after completing a prior
             Pegylated Interferon/Ribavirin (Peg-IFN/RBV) regimen

          -  Is of non childbearing potential or agrees to avoid becoming pregnant or impregnating
             a partner beginning at least 2 weeks prior to administration of the initial dose of
             study drug and for 14 days after the last dose of study drug if not taking RBV, or
             for 6 months after the last dose of study drug if taking RBV (or longer if dictated
             by local regulations). If not abstinent from heterosexual activity, participants in
             Part A must use 2 acceptable forms of barrier contraception whereas participants in
             Parts B and C must use 2 acceptable forms of contraception which may include oral
             contraceptives

        Part B only:

          -  If coinfected with human immunodeficiency virus (HIV) is not currently on
             antiretroviral therapy (ART) and has no plans to initiate ART treatment while
             participating in this study OR has well-controlled HIV on ART.

          -  Has at least 1 viable antiretroviral regimen alternative beyond their current regimen
             in the event of HIV virologic failure and the development of anti-retroviral drug
             resistance.

        Exclusion Criteria:

        Parts A, B, and C (unless otherwise specified):

          -  Has evidence of decompensated liver disease manifested by the presence of or history
             of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other
             signs or symptoms of advanced liver disease.

          -  If cirrhotic (Part B only), is Child-Pugh Class B or C or has a Pugh-Turcotte (CPT)
             score &gt;5.

          -  Is coinfected with hepatitis B virus (Parts A, B, and C) or is coinfected with HIV
             (Part A only; HIV coinfected participants are eligible for Parts B and C).

          -  If coinfected with HIV, has a history of opportunistic infection in the preceding 6
             months prior to screening.

          -  Has a history of malignancy ≤5 years prior to signing informed consent except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
             or carcinoma in situ; or is under evaluation for other active or suspected
             malignancy.

          -  Has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of
             hepatocellular carcinoma (HCC) or is under evaluation for HCC.

          -  Has clinically-relevant drug or alcohol abuse within 12 months of screening.

          -  Is female and is pregnant or breastfeeding, or expecting to conceive or donate eggs
             from at least 2 weeks prior to Day 1 and 90 days after the last dose of study
             medication, or longer if dictated by local regulations OR a male subject who is
             expecting to donate sperm from at least 2 weeks prior to day 1 until 90 days after
             the last dose of study medication.

          -  Has any of the following conditions:

          -  Organ transplants (including hematopoietic stem cell transplants) other than cornea
             and hair.

          -  Poor venous access that precludes routine peripheral blood sampling required for this
             trial.

          -  History of gastric surgery (e.g., stapling, bypass) or a history of malabsorption
             disorders (e.g., celiac sprue disease).

          -  Current or history of any clinically significant cardiac abnormalities/dysfunction,
             including but not limited to: angina, congestive heart failure, myocardial
             infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy,
             significant arrhythmia, uncontrolled hypertension, a history of use of antianginal or
             anti-arrythmic agents for cardiac conditions, prolonged ECG QTc interval (&gt;470 ms for
             males or &gt;480 ms for females by either the Bazett or Fridericia formula) at the
             screening visit, personal or family history of Torsade de pointes.

          -  Chronic pulmonary disease, including but not limited to: clinically significant
             chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis,
             sarcoidosis.

          -  Central nervous system (CNS) trauma requiring intubation, intracranial pressure
             monitoring, brain meningeal or skull surgery, or resulting in seizure, coma,
             permanent neurologic deficits, abnormal brain imaging, or cerebral spinal fluid (CSF)
             leak. Prior brain hemorrhage and/or intracranial aneurysms (whether adequately
             repaired or not).

          -  Current or history of seizure disorder unless seizure was &gt;10 years ago, a single
             isolated event, no history of or current use of anti-seizure medications prescribed,
             and a normal neurological examination is documented in trial files within 6 months of
             Day 1.

          -  Has a history of stroke or transient ischemic attack.

          -  Has a history of a medical/surgical condition that resulted in hospitalization within
             the 3 months prior to enrollment, other than for minor elective procedures.

          -  Has medical/surgical conditions that may result in a need for hospitalization during
             the period of the study.

          -  Has any medical condition requiring, or likely to require, chronic systemic
             administration of corticosteroids, tumor necrosis factor (TNF) antagonists, or other
             immunosuppressant drugs during the course of the trial.

          -  Has any condition, prestudy laboratory or ECG abnormality or history of any illness,
             which, in the opinion of the investigator, might confound the results of the study or
             pose additional risk in administering the study drugs to the subject.

          -  Has had a life-threatening serious adverse event (SAE) during the screening period.

          -  Has evidence of history of chronic hepatitis not caused by HCV, including but not
             limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis,
             hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, alcoholic liver disease
             and autoimmune hepatitis Part C only: is a male whose female partner is/are pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0042)</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0010)</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0026)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0024)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0004)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0035)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0008)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0009)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0021)</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0003)</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0040)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0029)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0038)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0028)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0048)</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0039)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0014)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0016)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 3L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre Centre de l'information medicale de Merck Canada</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gert Andersen</last_name>
      <phone>45 44824475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Blazy</last_name>
      <phone>33 147548990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Sharon</last_name>
      <phone>972 9 9539310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (New Zealand) Ltd.,</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Australian Medical Information Centre</last_name>
      <phone>61 2 8988 8428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD International GmbH</name>
      <address>
        <city>Lucerne 6</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Mossdorf</last_name>
      <phone>41 58 618 33 79</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ltd.</name>
      <address>
        <city>Hoddesdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Toms</last_name>
      <phone>+44 (0) 1992 452475</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 11, 2015</lastchanged_date>
  <firstreceived_date>January 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
